|
1
|
Lamartina L, Grani G, Durante C and
Filetti S: Recent advances in managing differentiated thyroid
cancer. F1000Res. 7(86)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Motzer RJ, Hutson TE, Glen H, Michaelson
MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B,
et al: Lenvatinib, everolimus, and the combination in patients with
metastatic renal cell carcinoma: A randomised, phase 2, open-label,
multicentre trial. Lancet Oncol. 16:1473–1482. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fala L: Lenvima (Lenvatinib), a
multireceptor tyrosine kinase inhibitor, approved by the FDA for
the treatment of patients with differentiated thyroid cancer. Am
Health Drug Benefits. 8 (Spec Feature):176–179. 2015.PubMed/NCBI
|
|
5
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kim SY, Kim SM, Chang H, Kim BW, Lee YS,
Chang HS and Park CS: Safety of tyrosine kinase inhibitors in
patients with differentiated thyroid cancer: Real-world use of
lenvatinib and sorafenib in Korea. Front Endocrinol (Lausanne).
10(384)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Krajewska J, Kukulska A and Jarzab B: Drug
safety evaluation of lenvatinib for thyroid cancer. Expert Opin
Drug Saf. 14:1935–1943. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schmidinger M: Understanding and managing
toxicities of vascular endothelial growth factor (VEGF) inhibitors.
EJC. (Suppl 11):172–191. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Capozzi M, De Divitiis C, Ottaiano A, von
Arx C, Scala S, Tatangelo F, Delrio P and Tafuto S: Lenvatinib, a
molecule with versatile application: From preclinical evidence to
future development in anti-cancer treatment. Cancer Manag Res.
11:3847–3860. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Laor E, Palmer LS, Tolia BM, Reid RE and
Winter HI: Outcome prediction in patients with Fournier's gangrene.
J Urol. 154:89–92. 1995.PubMed/NCBI
|
|
11
|
Singh A, Ahmed K, Aydin A, Khan MS and
Dasgupta P: Fournier's gangrene. A clinical review. Arch Ital Urol
Androl. 88:157–164. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Naranjo CA, Busto U, Sellers EM, Sandor P,
Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method
for estimating the probability of adverse drug reactions. Clin
Pharmacol Ther. 30:239–245. 1981.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jones JK: Adverse drug reactions in the
community health setting: Approaches to recognizing, counseling,
and reporting. Fam Community Health. 5:58–67. 1982.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shamloo BK, Chhabra P, Freedman AN,
Potosky A, Malin J and Weiss Smith S: Novel adverse events of
bevacizumab in the US FDA adverse event reporting system database:
A disproportionality analysis. Drug Saf. 35:507–518.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gamboa EO, Rehmus EH and Haller N:
Fournier's gangrene as a possible side effect of bevacizumab
therapy for resected colorectal cancer. Clin Colorectal Cancer.
9:55–58. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sendur MA, Aksoy S, Özdemir NY and Zengin
N: Necrotizing fasciitis secondary to bevacizumab treatment for
metastatic rectal adenocarcinoma. Indian J Pharmacol. 46:125–126.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ugai T, Norizuki M, Mikawa T, Ohji G and
Yaegashi M: Necrotizing fasciitis caused by Haemophilus influenzae
type b in a patient with rectal cancer treated with combined
bevacizumab and chemotherapy: A case report. BMC Infect Dis.
14(198)2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gonzaga-López A, Muñoz-Rodriguez J and
Ruiz-Casado A: Necrotising fasciitis in a patient treated with
FOLFIRI-aflibercept for colorectal cancer: A case report. Ann R
Coll Surg Engl. 99:e225–e226. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Piszczek J, Dalton B, Peters T, Ruether D
and Urbanski S: Extensive necrotizing fasciitis associated with
sunitinib therapy. Clin Genitourin Cancer. 12:e47–e49.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kuenen BC: Analysis of prothrombotic
mechanisms and endothelial perturbation during treatment with
angiogenesis inhibitors. Pathophysiol Haemost Thromb. 33 (Suppl
1):S13–S14. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Moriconi D, Cappagli V, Viola D, Molinaro
E, Agate L, Lorusso L, Egidi MF and Elisei R: Proteinuria is a late
onset adverse event in patients treated with cabozantinib: A single
center experience. Nephrol Dial Transpl. 33:i388–i38918. 2018.
|
|
22
|
Locati LD, Piovesan A, Durante C, Bregni
M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G,
et al: Real-world efficacy and safety of lenvatinib: Data from a
compassionate use in the treatment of radioactive iodine-refractory
differentiated thyroid cancer patients in Italy. Eur J Cancer.
118:35–40. 2019.PubMed/NCBI View Article : Google Scholar
|
